14.06
2.63%
0.36
Vorhandelsmarkt:
13.87
-0.19
-1.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$13.70
Offen:
$14
24-Stunden-Volumen:
887.52K
Relative Volume:
0.63
Marktkapitalisierung:
$639.31M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-16.94
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
+11.68%
1M Leistung:
+7.57%
6M Leistung:
+199.79%
1J Leistung:
+248.88%
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
14.06 | 639.31M | 27.10M | -24.31M | -33.33M | -0.83 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Brokers Issue Forecasts for CAPR FY2025 Earnings - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone - Yahoo Finance
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St
Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN
Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com
Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews
Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World
CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart
Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada
Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited - MSN
Capricor files cell therapy for DMD cardiomyopathy with FDA - pharmaphorum
Capricor completes U.S. marketing submission for lead candidate - MSN
Capricor completes BLA submission for deramiocel - The Pharma Letter
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor seeks U.S. marketing nod for DMD drug (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
Capricor completes FDA submission for DMD therapy By Investing.com - Investing.com Canada
Capricor Therapeutics Completes Submission of Biologics - GlobeNewswire
(CAPR) Trading Report - Stock Traders Daily
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Increase in Short Interest - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in December - MarketBeat
Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
State Street Corp Has $7.79 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9%What's Next? - MarketBeat
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Capricor Therapeutics (NASDAQ:CAPR) Trading 5.6% HigherWhat's Next? - MarketBeat
(CAPR) Trading Advice - Stock Traders Daily
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
The Manufacturers Life Insurance Company Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - MarketBeat
BNP Paribas Financial Markets Buys 15,872 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3%Here's Why - MarketBeat
Capricor Therapeutics (CAPR) Stock Drops Amid Volatile Biotech Sector - GuruFocus.com
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
(CAPR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P. - MarketBeat
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):